Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
Location: United States, California, Irvine
Employees: 11-50
Founded date: 2021
Investors 2
| Date | Name | Website |
| 22.09.2024 | T1D Fund | t1dfund.or... |
| 08.08.2024 | Newpath Ma... | newpath.pa... |
Mentions in press and media 2
| Date | Title | Description |
| 29.10.2024 | Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share an... |
| 04.11.2021 | Eledon Pharmaceuticals Announces Participation in November Conferences | IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requir... |